Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Statins Make Sense In Lower CV Risk Patients, WellPoint Asserts

Executive Summary

Generic statins can provide equal cardiovascular benefits - particularly in patients with low to moderate risk of cardiovascular events - while offering substantial cost savings over brand-name drugs, according to a study recently released by WellPoint

You may also be interested in...

Express Scripts Adds Lipitor Back Onto Preferred Formulary

Citing improved rebate terms, Express Scripts is including Pfizer's Lipitor on its National Preferred Formulary for the first time since January 2006

WellPoint Offers Simvastatin Free Trial; Preferred Brand Lipitor Left In Dust?

WellPoint beneficiaries will be able to receive up to four months of generic simvastatin as an incentive to switch from a branded cholesterol-lowering agent

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts